Relmada shareholders elect director, ratify auditor, approve 2M share increase to 2021 equity plan

RELMADA THERAPEUTICS, INC.

Annual meeting held May 23, 2025; 53.6% quorum attained.
John Glasspool elected Class I director (36-month term) with 7.14M for, 2.60M withheld.
Ratification of CBIZ CPAs as auditor for FY2025 approved: 16.44M for, 0.86M against.
Amendment to 2021 Plan approved: share pool increased by 2,000,000 to 9,900,000 total.
Continuing Class II directors: Charles Casamento and Sergio Traversa; Class III: John Glasspool and Paul Kelly.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.